Evidence map›Paper›PMID 39125026›Full record

ArticleMolecules (Basel, Switzerland)2024

Lysosomal Activation Mediated by Endocytosis in J774 Cell Culture Treated with N-Trimethyl Chitosan Nanoparticles.

Brenda I Magaña-Trejo, Aldo Y Tenorio-Barajas, Bulmaro Cisneros, Victor Altuzar, Sergio Tomas-Velázquez, Claudia Mendoza-Barrera, Efrain Garrido

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. New NaBMC chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brenda I Magaña-TrejoDepartamento de Genética y Biología Molecular, Centro de Investigación y Estudios Avanzados del IPN, Mexico City 07360, Mexico.ORCID 0000-0002-1652-1754
Aldo Y Tenorio-BarajasFacultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.ORCID 0000-0001-7256-5199
Bulmaro CisnerosDepartamento de Genética y Biología Molecular, Centro de Investigación y Estudios Avanzados del IPN, Mexico City 07360, Mexico.
Victor AltuzarFacultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.
Sergio Tomas-VelázquezDepartamento de Física, Centro de Investigación y Estudios Avanzados del IPN, Mexico City 07360, Mexico.
Claudia Mendoza-BarreraFacultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.ORCID 0000-0002-6544-1312
Efrain GarridoDepartamento de Genética y Biología Molecular, Centro de Investigación y Estudios Avanzados del IPN, Mexico City 07360, Mexico.

Funding

Consejo Nacional de Humanidades, Ciencias y Tecnologías SEP-CONACYT 286652, 2018-000068-02NACF-29222, 256514, and CF-2023-I-1178
6 · The paper itself

Abstract

Safety and effectiveness are the cornerstone objectives of nanomedicine in developing nanotherapies. It is crucial to understand the biological interactions between nanoparticles and immune cells. This study focuses on the manufacture by the microfluidic technique of N-trimethyl chitosan/protein nanocarriers and their interaction with J774 cells to elucidate the cellular processes involved in absorption and their impact on the immune system, mainly through endocytosis, activation of lysosomes and intracellular degradation. TEM of the manufactured nanoparticles showed spherical morphology with an average diameter ranging from 36 ± 16 nm to 179 ± 92 nm, depending on the concentration of the cargo protein (0, 12, 55 μg/mL). FTIR showed the crosslinking between N-trimethyl chitosan and the sodium tripolyphosphate and the α-helix binding loss of BSA. TGA revealed an increase in the thermal stability of N-trimethyl chitosan/protein nanoparticles compared with the powder. The encapsulation of the cargo protein used was demonstrated using XPS. Their potential to improve cell permeability and use as nanocarriers in future vaccine formulations was demonstrated. The toxicity of the nanoparticles in HaCaT and J774 cells was studied, as well as the importance of evaluating the differentiation status of J774 cells. Thus, possible endocytosis pathways and their impact on the immune response were discussed. This allowed us to conclude that N-trimethyl chitosan nanoparticles show potential as carriers for the immune system. Still, more studies are required to understand their effectiveness and possible use in therapies.

Indexed as

ChitosanEndocytosisLysosomesNanoparticlesAnimalsCell LineCell SurvivalDrug CarriersHumansMiceParticle SizeSerum Albumin, BovineChitosanDrug CarriersN-trimethyl chitosan chlorideSerum Albumin, Bovineencapsulationendocytosisimmune systemnanoparticlesN-trimethyl chitosan

Identifiers

PMID39125026
PMCPMC11313802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.